1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Teva Backs Small Molecule CGRP Approach To Migraine With Heptares Deal

 
• By Sukaina Virji

Teva Pharmaceutical Industries Ltd. has signed an exclusive licensing agreement for Heptares Therapeutics' small-molecule calcitonin gene-related peptide (CGRP) antagonist program for the treatment of migraine. A wave of biologicals targeting the CGRP pathway are approaching late-stage development, but Heptares CEO Malcolm Weir believes that small molecule CGRP antagonists "present the opportunity for delivery using routes that are not available to biologics, such as oral or intra-nasal, and for patients with different needs, such as in acute therapy," he told Scrip.

Teva Pharmaceutical Industries Ltd. has signed an exclusive licensing agreement for Heptares Therapeutics' small-molecule calcitonin gene-related peptide (CGRP) antagonist program for the treatment of migraine. A wave of biologicals targeting the CGRP pathway are approaching late-stage development, but Heptares CEO Malcolm Weir believes that small molecule CGRP antagonists "present the opportunity for delivery using routes that are not available to biologics, such as oral or intra-nasal, and for patients with different needs, such as in acute therapy," he told Scrip.

"CGRP is a well validated target for migraine but getting good small molecules for it have proved difficult because it's...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Atai Gives Up On Recognify’s Schizophrenia Drug After Phase IIb Miss

 
• By Joseph Haas

Set to merge with Beckley Psytech, Atai will focus on psychedelic candidates for treatment-resistant depression while Recognify will analyze Phase IIb data for possible next steps.

Roche Unveils Alzheimer’s Phase III Plan And Preclinical Study

 
• By Andrew McConaghie

The trontinemab Phase III study is due to get underway this year, with Roche confident its brainshuttle technology will help it surpass approved rivals.

More from Therapy Areas

Biogen Edges Closer To Growth On Strong Q2

 
• By Jessica Merrill

Sales of Leqembi, Zurzuvae and Skyclarys contributed to Biogen’s sales and earnings guidance raise, positioning the company closer to potential growth.

Amvuttra Makes Strong ATTR-CM Showing As Alnylam Prepares For Global Launches

 
• By Alaric DeArment

In an interview, chief commercial officer Tolga Tanguler gave some ideas of what to expect as the company prepares to launch the drug for ATTR-CM in Europe.

Argenx Powers Ahead With Vyvgart’s Prefilled Syringe Launch

 
• By Andrew McConaghie

The Netherlands-headquartered company is enjoying huge success with Vyvgart in two autoimmune conditions, with a new prefilled syringe version reaching more patient groups.